Annual General Meeting of Infant Bacterial Therapeutics
May 04, 2022 10:00 ET | Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2022 10:00 ET | Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Energy Management Corporation Announces New Location
April 07, 2022 11:00 ET | Energy Management Corporation
LAS VEGAS, April 07, 2022 (GLOBE NEWSWIRE) -- Energy Management Corporation (EMC) has announced the opening of a new location in Clark County, Nevada.  "I'm excited that we are able to build upon...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
April 05, 2022 14:00 ET | Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 05, 2022 14:00 ET | Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
VAXIMM_LOGO_CMYK_300dpi.jpg
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
March 08, 2022 02:00 ET | VAXIMM AG
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen fieldNEC OncoImmunity to initiate first clinical trial...
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
January 19, 2022 17:30 ET | Infant Bacterial Therapeutics AB
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...
The Connection Study fortsätter efter planerad säkerhetsanalys av Data Monitoring Committee (DMC)
January 19, 2022 17:30 ET | Infant Bacterial Therapeutics AB
Den 30 september, 2021 meddelade Infant Bacterial Therapeutics (IBT) att företaget nått en viktig milstolpe i utvecklingen av IBP-9414, efter att ha rekryterat 600 för tidigt födda barn till The...
Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
January 10, 2022 16:30 ET | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Australien
January 10, 2022 16:30 ET | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverket i Australien utfärdat ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar...